TLDR
- enGene shares skyrocket 50% after strong Phase 2 bladder cancer trial data.
- Phase 2 results lift enGene Holdings stock as detalimogene shows solid efficacy.
- enGene surges after detailing improved cancer response rates in updated trial.
- Positive Phase 2 data sends enGene stock soaring past $9 on strong momentum.
- enGene’s detalimogene success fuels a 50% rally amid bullish biotech sentiment.
EnGene Holdings(ENGN) shares surged more than 50% to trade at $9.18 after releasing positive Phase 2 clinical data.
enGene Holdings Inc., ENGN
The sharp price increase reflected strong market confidence in the company’s genetic medicine platform. The stock demonstrated firm momentum as it consolidated around the $9 mark after an early-session spike.
The clinical-stage company announced encouraging preliminary results from its ongoing Phase 2 LEGEND trial of detalimogene voraplasmid in high-risk bladder cancer. The latest data reinforced ENGN’s advancing position in the non-viral gene therapy segment. The company confirmed that it remains on track to file a Biologics License Application in the second half of 2026.
The LEGEND trial focused on patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. ENGN evaluated efficacy under an amended protocol that aligned with American Urological Association Guidelines. This adjustment improved the trial’s consistency with standard-of-care practices.
Improved Response Rates and Safety Profile Under Amended Protocol
The preliminary analysis included 62 patients with at least one post-baseline assessment under the updated protocol. ENGN reported a 63% complete response rate at any time and a 56% rate at three months. At six months, 62% of patients maintained complete response, showing a notable improvement from earlier results.
All five patients who reached the nine-month mark remained in complete response, highlighting sustained efficacy. The company noted that four patients achieved complete response after reinduction, demonstrating continued therapeutic benefit. ENGN emphasized that detalimogene showed a competitive efficacy and favorable tolerability profile.
The trial completed enrollment of 125 patients, surpassing the initial target by 25%. About 42% of participants experienced treatment-related adverse events, but most were mild. Only a small fraction required dose interruptions or discontinuations, indicating manageable side effects.
Path Toward Regulatory Submission and Commercial Potential
ENGN plans to advance detalimogene toward regulatory submission in 2026, supported by strong data and protocol optimization. The company highlighted detalimogene’s potential to become a first-line therapy for high-risk bladder cancer. Its non-viral delivery approach and ease of administration may offer a significant advantage over existing treatments.
In September 2024, the company released earlier data from patients treated before the amendment, which showed lower response rates. The new analysis underscored the value of the revised design, enhancing both consistency and performance. ENGN continues to strengthen its clinical momentum and expand its therapeutic footprint.
With promising efficacy, tolerability, and commercial potential, ENGN positions itself for long-term growth in genetic medicines. The stock’s sharp rise reflected growing optimism about the company’s future trajectory and late-stage progress. As detalimogene moves closer to regulatory review, ENGN remains firmly in focus within the biotech sector.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
